Treatment Satisfaction With Omnipod DASH in Adults With Type 1 Diabetes: A Nonblinded 1:1 Randomized Controlled Trial.

PAID scores were lower after 12 weeks of device use (20.0 [13.4] at baseline to 13.5 [11.5] at extension end; P = .048), but the reduction did not reach statistical significance at 24 weeks compared with baseline (24.9 [13.6] at baseline to 20.1 [14.1] at extension end; P = .17) (see Fig. 6 ).

also in 111,027 other papers